Table A9.
Parameter values varied in probabilistic sensitivity analyses.
| Parameter | Value | SE | Distribution |
|---|---|---|---|
| Patient Characteristics | |||
| Bodyweight | 81.8 kg | 1.95296 | Normal |
| BSA | 1.978 m2 | 0.026997 | Normal |
| Resource Use | |||
| Pre-Progression Resource Use: Full blood count | 0.33 | 0.066667 | Gamma |
| Pre-Progression Resource Use: X-ray | 0.17 | 0.033333 | Gamma |
| Pre-Progression Resource Use: Blood glucose | 0.33 | 0.066667 | Gamma |
| Pre-Progression Resource Use: Lactate dehydrogenase | 0.33 | 0.066667 | Gamma |
| Pre-Progression Resource Use: CT Scan | 0.17 | 0.033333 | Gamma |
| Pre-Progression Resource Use: Office visit | 0.17 | 0.033333 | Gamma |
| Post-Progression Resource Use: Full blood count | 1.00 | 0.2 | Gamma |
| Post-Progression Resource Use: X-ray | 0.33 | 0.066667 | Gamma |
| Post-Progression Resource Use: Blood glucose | 1.00 | 0.2 | Gamma |
| Post-Progression Resource Use: Lactate dehydrogenase | 1.00 | 0.2 | Gamma |
| Post-Progression Resource Use: Office visit | 1.00 | 0.2 | Gamma |
| Post-Progression Resource Use: CT Scan | 0.33 | 0.066667 | Gamma |
| Post-Progression Resource Use: Hospitalization | 0.08 | 0.016667 | Gamma |
| End-of-life Palliative care (one-off) | 1 | 0.20 | Gamma |
| Apheresis: One-Time cost | CAD 1392.37 | CAD 278.47 | Gamma |
| Tecartus Proportion ICU Stay | 0.22 | 0.04 | Beta |
| Hospital days, proportion ICU | 18 | 22.5 | Normal |
| Hospital days, proportion non-ICU | 16.50 | 10.75 | Normal |
| Proportion requiring bridging therapy | 0.37 | 0.03 | Beta |
| Cost: Initial Hospitalization: Intensive Care Unit Day | CAD 8343.73 | CAD 1668.75 | Gamma |
| Cost: Initial Hospitalization: Inpatient Day (Non-ICU) | CAD 1580.53 | CAD 316.11 | Gamma |
| Cost: Stem cell transplant | CAD 166,855.53 | CAD 33,371.11 | Gamma |
| Cost: Office visit | CAD 174.64 | CAD 34.93 | Gamma |
| Cost: Palliative care (one-off) | CAD 35,262.48 | CAD 7052.50 | Gamma |
| Cost: Full blood count | CAD 4.12 | CAD 0.82 | Gamma |
| Cost: X-ray | CAD 23.15 | CAD 4.63 | Gamma |
| Cost: Blood glucose | CAD 1.33 | CAD 0.27 | Gamma |
| Cost: Lactate dehydrogenase | CAD 1.33 | CAD 0.27 | Gamma |
| Cost: Inpatient stay | CAD 1580.53 | CAD 316.11 | Gamma |
| Cost: CT Scan | CAD 195.00 | CAD 39.00 | Gamma |
| Cost: Hospitalization | CAD 13,215.84 | CAD 2643.17 | Gamma |
| Utility | |||
| Utility: Pre-progression (up to 60 months) | 0.78 | 0.01 | Beta |
| Utility: Pre-progression, cured (beyond 60 months) | 0.7851841 | 0.01 | Beta |
| Utility: Post-progression | 0.68 | 0.024 | Beta |
| Adverse Events | |||
| Brexucabtagene autoleucel AE incidence: Cytokine release syndrome (CRS) | 62% | 0.059 | Beta |
| Brexucabtagene autoleucel AE incidence: Pyrexia | 15% | 0.043 | Beta |
| Brexucabtagene autoleucel AE incidence: Anaemia | 51% | 0.061 | Beta |
| Brexucabtagene autoleucel AE incidence: Platelet Count decreased | 38% | 0.059 | Beta |
| Brexucabtagene autoleucel AE incidence: Hypotension | 22% | 0.050 | Beta |
| Brexucabtagene autoleucel AE incidence: Neutrophil count decreased | 53% | 0.061 | Beta |
| Brexucabtagene autoleucel AE incidence: White blood cell count decreased | 41% | 0.060 | Beta |
| Brexucabtagene autoleucel AE incidence: Hypoxia | 21% | 0.049 | Beta |
| Brexucabtagene autoleucel AE incidence: Hypophosphataemia | 22% | 0.050 | Beta |
| Brexucabtagene autoleucel AE incidence: Neutropenia | 34% | 0.057 | Beta |
| Brexucabtagene autoleucel AE incidence: Hyponatraemia | 10% | 0.037 | Beta |
| Brexucabtagene autoleucel AE incidence: Alanine aminotransferase increased | 9% | 0.034 | Beta |
| Brexucabtagene autoleucel AE incidence: Encephalopathy | 18% | 0.046 | Beta |
| Brexucabtagene autoleucel AE incidence: Hypokalaemia | 15% | 0.043 | Beta |
| Brexucabtagene autoleucel AE incidence: Hypocalcaemia | 9% | 0.034 | Beta |
| Brexucabtagene autoleucel AE incidence: Thrombocytopenia | 16% | 0.045 | Beta |
| Brexucabtagene autoleucel AE incidence: Aspartate aminotransferase increased | 10% | 0.037 | Beta |
| Brexucabtagene autoleucel AE incidence: Confusional state | 12% | 0.039 | Beta |
| Brexucabtagene autoleucel AE incidence: Hypertension | 13% | 0.041 | Beta |
| Brexucabtagene autoleucel AE incidence: Acute Kidney Injury | 7% | 0.032 | Beta |
| Brexucabtagene autoleucel AE incidence: Leukopenia | 15% | 0.043 | Beta |
| Brexucabtagene autoleucel AE incidence: Lymphocyte count decreased | 9% | 0.034 | Beta |
| Brexucabtagene autoleucel AE incidence: Pneumonia | 13% | 0.041 | Beta |
| Brexucabtagene autoleucel AE incidence: Respiratory Failure | 6% | 0.029 | Beta |
| Brexucabtagene autoleucel AE incidence: Sepsis | 6% | 0.029 | Beta |
| Disutility Cytokine release syndrome | 0.78 | 0.156 | Beta |
| Disutility Pyrexia | 0.11 | 0.022 | Beta |
| Disutility Anaemia | 0.12 | 0.024 | Beta |
| Disutility Platelet Count decreased | 0.11 | 0.022 | Beta |
| Disutility Hypotension | 0.15 | 0.03 | Beta |
| Disutility Neutrophil count decreased | 0.15 | 0.03 | Beta |
| Disutility White blood cell count decreased | 0.15 | 0.03 | Beta |
| Disutility Hypoxia | 0.11 | 0.022 | Beta |
| Disutility Hypophosphataemia | 0.15 | 0.03 | Beta |
| Disutility Neutropenia | 0.09 | 0.018 | Beta |
| Disutility Hyponatraemia | 0.15 | 0.03 | Beta |
| Disutility Alanine aminotransferase increased | 0.15 | 0.03 | Beta |
| Disutility Encephalopathy | 0.15 | 0.03 | Beta |
| Disutility Hypokalaemia | 0.15 | 0.03 | Beta |
| Disutility Hypocalcaemia | 0.15 | 0.03 | Beta |
| Disutility Thrombocytopenia | 0.11 | 0.022 | Beta |
| Disutility Aspartate aminotransferase increased | 0.15 | 0.03 | Beta |
| Disutility Confusional state | 0.15 | 0.03 | Beta |
| Disutility Hypertension | 0.15 | 0.03 | Beta |
| Disutility Acute Kidney Injury | 0.15 | 0.03 | Beta |
| Disutility Leukopenia | 0.15 | 0.03 | Beta |
| Disutility Lymphocyte count decreased | 0.15 | 0.03 | Beta |
| Disutility Pneumonia | 0.15 | 0.03 | Beta |
| Disutility Respiratory Failure | 0.15 | 0.03 | Beta |
| Disutility Sepsis | 0.15 | 0.03 | Beta |
| Duration Cytokine release syndrome | 4 | 0.8 | Gamma |
| Duration Pyrexia | 2 | 0.4 | Gamma |
| Duration Anaemia | 14 | 2.8 | Gamma |
| Duration Platelet Count decreased | 50 | 10 | Gamma |
| Duration Hypotension | 5 | 1 | Gamma |
| Duration Neutrophil count decreased | 17 | 3.4 | Gamma |
| Duration White blood cell count decreased | 40 | 8 | Gamma |
| Duration Hypoxia | 2 | 0.4 | Gamma |
| Duration Hypophosphataemia | 5 | 1 | Gamma |
| Duration Neutropenia | 47 | 9.4 | Gamma |
| Duration Hyponatraemia | 7 | 1.4 | Gamma |
| Duration Alanine aminotransferase increased | 7 | 1.4 | Gamma |
| Duration Encephalopathy | 9 | 1.8 | Gamma |
| Duration Hypokalaemia | 7 | 1.4 | Gamma |
| Duration Hypocalcaemia | 7 | 1.4 | Gamma |
| Duration Thrombocytopenia | 63 | 12.6 | Gamma |
| Duration Aspartate aminotransferase increased | 7 | 1.4 | Gamma |
| Duration Confusional state | 7 | 1.4 | Gamma |
| Duration Hypertension | 5 | 1 | Gamma |
| Duration Acute Kidney Injury | 7 | 1.4 | Gamma |
| Duration Leukopenia | 21 | 4.2 | Gamma |
| Duration Lymphocyte count decreased | 64 | 12.8 | Gamma |
| Duration Pneumonia | 7 | 1.4 | Gamma |
| Duration Respiratory Failure | 7 | 1.4 | Gamma |
| Duration Sepsis | 7 | 1.4 | Gamma |
| AE cost: Cytokine release syndrome | CAD 18,366.96 | CAD 3673.39 | Gamma |
Abbreviations: BSA = body surface area; AE = adverse events; ICU intensive care unit.